NZ$1.99
2.32%
New Zealand Exchange, Fri, Sep 18 2026.
ISIN
NZRYME0001S4
Symbol
RYM

Ryman Healthcare Target price 2026 - Analyst rating & recommendation

Ryman Healthcare Classifications & Recommendation

Buy
78%
Hold
22%

Ryman Healthcare Price Target

Target Price NZ$2.87
Price NZ$1.99
Potential
Number of Estimates 6
6 Analysts have issued a price target Ryman Healthcare 2027 . The average Ryman Healthcare target price is NZ$2.87. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend Ryman Healthcare to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ryman Healthcare stock has an average upside potential 2027 of . Most analysts recommend the Ryman Healthcare stock at Purchase.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Mar '26 2027
Estimates
Revenue Million NZ$ 855.59 936.72
12.47% 9.48%
EBITDA Margin 9.57% 18.21%
291.07% 90.24%
Net Margin -20.03% 8.43%
70.35% 142.09%

6 Analysts have issued a sales forecast Ryman Healthcare 2027 . The average Ryman Healthcare sales estimate is

NZ$937m
unlock
. This is
9.48% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
NZ$1.1b 25.88%
unlock
, the lowest is
NZ$864m 0.93%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 NZ$856m 12.47%
2027
NZ$937m 9.48%
unlock
2028
NZ$1.0b 7.08%
unlock
2029
NZ$1.1b 7.08%
unlock

6 Analysts have issued an Ryman Healthcare EBITDA forecast 2027. The average Ryman Healthcare EBITDA estimate is

NZ$171m
unlock
. This is
108.28% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
NZ$290m 253.85%
unlock
, the lowest is
NZ$83.3m 1.75%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2026 NZ$81.9m 339.85%
2027
NZ$171m 108.28%
unlock
2028
NZ$215m 26.02%
unlock
2029
NZ$249m 15.98%
unlock

EBITDA Margin

2026 9.57% 291.07%
2027
18.21% 90.24%
unlock
2028
21.43% 17.68%
unlock
2029
23.21% 8.31%
unlock

5 Ryman Healthcare Analysts have issued a net profit forecast 2027. The average Ryman Healthcare net profit estimate is

NZ$78.9m
unlock
. This is
146.06% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
NZ$141m 182.09%
unlock
, the lowest is
NZ$-16.9m 90.13%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 NZ$-171m 66.65%
2027
NZ$78.9m 146.06%
unlock
2028
NZ$130m 65.25%
unlock
2029
NZ$176m 34.58%
unlock

Net Margin

2026 -20.03% 70.35%
2027
8.43% 142.09%
unlock
2028
13.00% 54.21%
unlock
2029
16.34% 25.69%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Mar '26 2027
Estimates
Earnings Per Share NZ$ -0.17 0.08
76.39% 147.06%
P/E 24.95
EV/Sales 10.39

5 Analysts have issued a Ryman Healthcare forecast for earnings per share. The average Ryman Healthcare EPS is

NZ$0.08
unlock
. This is
147.06% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
NZ$0.14 182.35%
unlock
, the lowest is
NZ$-0.02 88.24%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 NZ$-0.17 76.39%
2027
NZ$0.08 147.06%
unlock
2028
NZ$0.13 62.50%
unlock
2029
NZ$0.17 30.77%
unlock

P/E ratio

Current -11.41 216.23%
2027
24.95 318.63%
unlock
2028
15.09 39.52%
unlock
2029
11.22 25.65%
unlock

Based on analysts' sales estimates for 2027, the Ryman Healthcare stock is valued at an EV/Sales of

10.39
unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 11.38 105.79%
2027
10.39 8.68%
unlock
2028
9.71 6.61%
unlock
2029
9.06 6.61%
unlock

P/S ratio

Current 2.32 30.08%
2027
2.12 8.66%
unlock
2028
1.98 6.61%
unlock
2029
1.85 6.61%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today